Schering Sees PEG-Intron Market Share Begin To Stabilize
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. market share for Schering-Plough's hepatitis C treatment PEG-Intron (pegylated interferon) is starting to stabilize, Global Pharmaceutical President Carrie Cox said.